The lack of Canadian capacity to produce COVID-19 vaccines has raised new questions on how governments should approach the pharmaceutical industry. Amid calls for Canada to create a better investment environment for pharmaceutical companies, some are advising caution to avoid overcompensation and a culture that could foster over-prescription, instead suggesting a more results-based approach. Walter Robinson, a consultant who has spent most of the past 15 years in leadership positions in and around the life sciences sector including at a pharmaceutical trade association, says the vaccine issue is only a symptom of a larger problem. “If people are just saying, ‘Well, we need more manufacturing capacity,’ they’re not asking the right questions and they’re coming up with the wrong answer,” Robinson said in an interview. He says the government’s view of the life sciences sector has been focused on managing and containing the cost. While that’s a legitimate public policy …